PARIS – Lancôme is collaborating with Swiss longevity biotech company Timeline on a new skin care line.

It will be presented at the American Academy of Dermatology in Denver, Colorado, which runs March 27 to 29.

“Longevity is a frontier of radical scientific progress, and we believe that will shape the future of beauty,” said Vania Lacascade, global brand president of Lancôme. “It fully aligns with what women want today – to live better, not just longer.”

In 2024, Lancôme’s parent L’Oréal invested in Timeline, and they kicked off a joint research alliance.

Lancôme’s collaboration centers on Mitopure, Timeline’s proprietary molecule with more than $50 million in backing and 15 years of research-and-development. Mitopure is a very pure form of Urolithin A, a postbiotic clinically proven to re-energize mitochondria, which generate most of the energy necessary to power cells’ chemical reactions. The cellular renewal process is called mitophagy.

L’Oréal and Timeline have been exploring how Mitopure can impact the key hallmarks of skin aging. The new skin care products combine Mitopure with Lancôme’s proprietary compounds for what’s billed to be longevity benefits.

Lacascade explained that as one of the leading luxury players, Lancôme has “a responsibility to share knowledge, raise standards and approach aging with this more inclusive and optimistic vision. What we like about longevity is that it is a proactive, science-led approach that acts at the root of aging mechanisms. It’s not a trend; it is a scientific reality.”

Lancôme aims to place longevity at the heart of beauty and focus on skin health all throughout a person’s life.

“It’s moving from reactive correction to proactive and data-driven care,” Lacascade said.

Lancôme’s approach is to translate such scientific progress into daily longevity luxury beauty products. For the new line’s creation, the brand brought knowledge in skin biology, formulation and diagnostic expertise. Timeline contributed expertise in longevity science with Mitopure, which was initially developed for oral supplements.

“We started by showing its benefits in humans, for both muscle and immunity, and we’re really excited to see how its benefits have translated over into skin longevity,” said Chris Rinsch, cofounder and president of Timeline. This includes the promotion of collagen health and synthesis.

“We want the most people possible to benefit from these discoveries that we’re making,” he said. “Lancôme is really enabling this.”

The new products – still under wraps – will be what Lacascade described as “high-performing, sensorial, luxury formulas” designed to act on skin’s biological age. That will be measurable with Cell BioPrint that is like a lab on a chip capable of modeling aging trajectories, as well.

Lancôme partnered with Korean startup NanoEnTek on Cell BioPrint.

Lancôme also delved into the realm of longevity in 2025, when the brand launched Absolue Longevity The Soft Cream. Its formula has Absolue PDRN, said to augment cells’ longevity mechanism to extend the skin’s youthfulness.

“This will mark the first deployment of Mitopure at global scale through a major beauty brand,” Lacascade said of the upcoming range.

Rinsch sees similarities between Lancôme and Timeline, not least that both focus on creating scientific breakthroughs.

“We believe that together we’re going to create a new category that disrupts this traditional anti-aging approach, with the clinically validated longevity protocols for skin health span,” he said.